Indazole Derivatives as Emerging Scaffolds for Anti-Breast Cancer Therapy: Synthesis, Structure-Activity Relationship, and Therapeutic Potential.

Authors

Soubhik Tanti, Akhilesh Gangwar, Vikas Jaitak

Published in

Archiv der Pharmazie. Volume 359. Issue 11.

Abstract

Breast cancer (BC) is the second most common cause of death in women. Current therapies like hormonal therapy, surgery, radiotherapy, and chemotherapy become ineffective due to severe side effects and multidrug resistance. Therefore, there is an urgent need for the development of more effective and safer anti-BC agents. Among different classes of heterocyclic molecules, indazole-based derivatives have emerged as potent anti-BC agents due to their versatile structural features and wide range of biological targets. Indazole is a benzene-pyrazole fused system with potential biological therapeutic significance. This review provides a detailed overview of recent progress in strategies that have expanded the accessible structural diversity of this scaffold. Moreover, mechanistic insights reveal that indazole derivatives mediate their antitumor effects through multi-target modulation, including the inhibition of key kinases such as EGFR, VEGFR, and CDKs, perturbation of microtubule function, activation of apoptotic pathways, and modulation of hormone receptor-dependent signalling, along with SAR. Collectively, this article is a BC-focused integration of different synthetic approaches, the key molecular targets for therapy, and studies showing which groups are responsible for their anti-BC potential, focusing on the latest research published.

PMID:
42956263
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.